ATE498683T1 - Leptin antagonisten - Google Patents
Leptin antagonistenInfo
- Publication number
- ATE498683T1 ATE498683T1 AT05809259T AT05809259T ATE498683T1 AT E498683 T1 ATE498683 T1 AT E498683T1 AT 05809259 T AT05809259 T AT 05809259T AT 05809259 T AT05809259 T AT 05809259T AT E498683 T1 ATE498683 T1 AT E498683T1
- Authority
- AT
- Austria
- Prior art keywords
- leptin
- leptin antagonists
- antagonists
- amino acid
- acid residues
- Prior art date
Links
- 102000016267 Leptin Human genes 0.000 title abstract 4
- 108010092277 Leptin Proteins 0.000 title abstract 4
- 239000005557 antagonist Substances 0.000 title abstract 3
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 title abstract 3
- 229940039781 leptin Drugs 0.000 title abstract 3
- 125000000539 amino acid group Chemical group 0.000 abstract 2
- 230000002209 hydrophobic effect Effects 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/996,607 US7307142B2 (en) | 2004-11-26 | 2004-11-26 | Leptin antagonists |
| PCT/IL2005/001250 WO2006056987A2 (en) | 2004-11-26 | 2005-11-24 | Leptin antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE498683T1 true ATE498683T1 (de) | 2011-03-15 |
Family
ID=36204374
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05809259T ATE498683T1 (de) | 2004-11-26 | 2005-11-24 | Leptin antagonisten |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7307142B2 (enExample) |
| EP (1) | EP1814986B1 (enExample) |
| JP (1) | JP5113526B2 (enExample) |
| CN (1) | CN101189335B (enExample) |
| AT (1) | ATE498683T1 (enExample) |
| DE (1) | DE602005026432D1 (enExample) |
| ES (1) | ES2363011T3 (enExample) |
| WO (1) | WO2006056987A2 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8227408B2 (en) * | 2005-09-07 | 2012-07-24 | Neurotez, Inc. | Leptin as an anti-amyloidogenic biologic and methods for delaying the onset and reducing Alzheimer's disease-like pathology |
| JP5622720B2 (ja) * | 2008-05-21 | 2014-11-12 | ニューロテスインコーポレイテッド | 神経原繊維変化に関連する進行性認知障害の治療方法 |
| CA2742600A1 (en) * | 2008-11-04 | 2010-05-14 | Nikolaos Tezapsidis | Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amlyoid beta |
| US8778890B2 (en) | 2009-03-31 | 2014-07-15 | Temple University—Of the Commonwealth System of Higher Education | Leptin antagonist and methods of use |
| CN102958531A (zh) * | 2010-04-22 | 2013-03-06 | 耶路撒冷希伯来大学伊森姆研究发展公司 | 高亲和力瘦蛋白和瘦蛋白拮抗剂 |
| WO2014024189A1 (en) * | 2012-08-06 | 2014-02-13 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd | Pegylated high affinity leptins with increased biological activity |
| IT1423968B1 (enExample) * | 2014-04-28 | 2016-08-26 | ||
| US10926006B2 (en) | 2015-02-26 | 2021-02-23 | Remodeless Cv Ltd | Drug eluting stent |
| US11123461B2 (en) | 2015-02-26 | 2021-09-21 | Remodeless Cv Ltd | Treatment of ischemia and reperfusion using leptin antagonist |
| CA2977607A1 (en) * | 2015-02-26 | 2016-09-01 | Jacob Schneiderman | Methods and compositions relating to leptin antagonists |
| CN104829708B (zh) * | 2015-05-06 | 2017-11-28 | 广东省生物资源应用研究所 | 一条d螺旋区突变的瘦素活性肽及其编码基因和应用 |
| CN104829707B (zh) * | 2015-05-06 | 2017-12-19 | 广东省生物资源应用研究所 | 一条cd环和e螺旋区突变的瘦素活性肽及其编码基因和应用 |
| WO2017013270A1 (en) | 2015-07-23 | 2017-01-26 | Universite De Strasbourg | Use of leptin signaling inhibitor for protecting kidneys from patients having ciliopathy |
| EA201991075A1 (ru) * | 2016-11-08 | 2019-10-31 | Антигенсвязывающие белки, которые проявляют антагонизм в отношении лептинового рецептора | |
| LT3773713T (lt) | 2018-04-06 | 2025-08-25 | Regeneron Pharmaceuticals, Inc. | Leptino receptoriaus agonistinis antikūnas, skirtas kaulų masės didinimui subjektui, kuriam pasireiškia medžiagų apykaitos sutrikimas arba hipoleptinemija |
| MX2021007394A (es) | 2018-12-18 | 2021-07-15 | Regeneron Pharma | Composiciones y metodos para aumentar el peso corporal y la masa muscular magra mediante el uso de antagonistas contra el receptor de leptina, gdf8 y activina a. |
| WO2024050285A2 (en) * | 2022-08-31 | 2024-03-07 | The Board Of Trustees Of The Leland Stanford Junior University | Leptin analogs for treating obesity and weight management |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6309853B1 (en) * | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| WO1997020933A2 (en) * | 1995-12-06 | 1997-06-12 | Schering Corporation | MUTATIONAL VARIANTS OF MAMMALIAN Ob GENE PROTEINS |
| US20020160935A1 (en) * | 2000-03-24 | 2002-10-31 | Smithkline Beecham Plc | Use of leptin antagonists for the treatment of diabetes |
| CA2266585A1 (en) * | 1996-09-20 | 1998-03-26 | Hoechst Aktiengesellschaft | Use of leptin antagonists for treating insulin resistance in type ii diabetes |
| RU2003125638A (ru) * | 2001-02-06 | 2005-03-10 | Мерк Патент ГмбХ (DE) | Модифицированный лептин с уменьшенной иммуногенностью |
-
2004
- 2004-11-26 US US10/996,607 patent/US7307142B2/en not_active Expired - Fee Related
-
2005
- 2005-11-24 EP EP05809259A patent/EP1814986B1/en not_active Expired - Lifetime
- 2005-11-24 WO PCT/IL2005/001250 patent/WO2006056987A2/en not_active Ceased
- 2005-11-24 JP JP2007542513A patent/JP5113526B2/ja not_active Expired - Fee Related
- 2005-11-24 CN CN2005800471206A patent/CN101189335B/zh not_active Expired - Fee Related
- 2005-11-24 DE DE602005026432T patent/DE602005026432D1/de not_active Expired - Lifetime
- 2005-11-24 AT AT05809259T patent/ATE498683T1/de not_active IP Right Cessation
- 2005-11-24 ES ES05809259T patent/ES2363011T3/es not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| DE602005026432D1 (de) | 2011-03-31 |
| WO2006056987A2 (en) | 2006-06-01 |
| EP1814986B1 (en) | 2011-02-16 |
| US7307142B2 (en) | 2007-12-11 |
| CN101189335A (zh) | 2008-05-28 |
| WO2006056987A3 (en) | 2006-08-24 |
| CN101189335B (zh) | 2012-01-11 |
| JP5113526B2 (ja) | 2013-01-09 |
| EP1814986A2 (en) | 2007-08-08 |
| JP2008521795A (ja) | 2008-06-26 |
| US20060154859A1 (en) | 2006-07-13 |
| ES2363011T3 (es) | 2011-07-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602005026432D1 (de) | Leptin antagonisten | |
| SA519410284B1 (ar) | Cd3 بنيات بولي ببتيد متعددة النوعية ذات ربط ل مقيد وطرق لاستخدامها | |
| DK3530673T3 (da) | Humaniserede anti-beta7-antagonister og anvendelser deraf | |
| EA201100070A1 (ru) | Туберкулезный белок rv2386c, композиции и их применения | |
| TW200745163A (en) | Peptides that block the binding of IgG to FcRn | |
| CY1113199T1 (el) | Σταθεροποιημενες συνθεσεις γλυκοσερεμπροσιδασης | |
| WO2006017538A3 (en) | Hk1-binding proteins | |
| DK2035447T3 (da) | Polypeptid | |
| MX2011011754A (es) | Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b. | |
| NO20065217L (no) | Polymerbasert forsinket frigjoringsutstyr | |
| MX2008011874A (es) | Composiciones estabilizadas de polipeptidos. | |
| MA32982B1 (fr) | Proteines de liaison au recepteur cgrp humain | |
| ATE428727T1 (de) | Neue, an den erythropoietinrezeptor bindende peptide | |
| AR070690A1 (es) | Metodos y composiciones que utilizan polipeptidos de fusion de klotho-fgf (factor de crecimiento de fibroblastos) | |
| WO2006138343A3 (en) | Compositions comprising receptor - associated protein (rap) variants specific for lrp2 and uses thereof | |
| TW200801036A (en) | RAGE fusion proteins, formulations, and methods of use thereof | |
| ATE514714T1 (de) | Hutnfr1-selektive antagonisten | |
| CR9637A (es) | Proteinas de enlace il-6 | |
| MA56397A (fr) | Protéines de liaison à l'il1rap | |
| EP1957094A4 (en) | CALCIUM-BINDING PEPTIDES | |
| ATE404225T1 (de) | Radiofluorierte peptide | |
| ATA19522003A (de) | Gag-bindungsproteine | |
| DK1737961T3 (da) | Modificerede bouganin proteiner, cytotoxiner og fremgangsmåder og anvendelser deraf | |
| WO2014150748A3 (en) | Stabilized single human cd4 domains and fusion proteins | |
| WO2008086035A3 (en) | Split mutant hydrolase fusion reporter and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |